Merck KGaA (MKGAY) News Today $38.36 0.00 (0.00%) (As of 08/1/2017) Add Compare Share Share Headlines Stock Analysis All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street TipRanks The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 February 2022 January 2022 December 2021 Time Period Merck in Cancer Licensing Pact With LaNova MedicinesNovember 14, 2024 | marketwatch.comMerck KGaA continues focus on strengthening pipeline with external innovation, says CFO on drug trialsNovember 14, 2024 | msn.comGermany’s Merck Expects Sales at Lower End of Outlook Range After Third-Quarter MissNovember 14, 2024 | wsj.comMerck’s Q3 earnings beat estimates, but company lowers guidance and stock dipsOctober 31, 2024 | marketwatch.comMerck sees Gardasil China woes carrying into 2025October 31, 2024 | msn.comLife science business investing $76M, adding 170 jobs at St. Louis facilityOctober 29, 2024 | bizjournals.comGermany's Merck open to more M&A for its Life Science divisionOctober 17, 2024 | msn.comMerck posts positive trial data for Capvaxive pneumonia vaccine in at-risk adultsOctober 16, 2024 | msn.comMerck opens new SOD facility in South KoreaOctober 14, 2024 | msn.comMerck (MRK) Outpaces Stock Market Gains: What You Should KnowOctober 9, 2024 | msn.comBarclays Remains a Buy on Merck & Company (MRK)October 7, 2024 | markets.businessinsider.comMerck Is At Support And Should Go Higher (Technical Analysis)October 7, 2024 | seekingalpha.comMerck Stock Falls After Rival Summit Beats Keytruda Cancer Drug in TrialSeptember 9, 2024 | msn.comMerck stops two more cancer trials over poor resultsAugust 29, 2024 | msn.comMerck KGaA (MKGAF): Morgan Stanley is Bullish on This European AI Stock NowAugust 16, 2024 | msn.comBNP PARIBAS EXANE Downgrades Merck KGaA (MKGAF)August 12, 2024 | msn.comMerck Buying Drug Targeting B-Cell Diseases for Up to $1.3 BillionAugust 9, 2024 | msn.comMerck KGaA (MKGAF) Q2 2024 Earnings Call TranscriptAugust 3, 2024 | seekingalpha.comMerck KGaA 2Q After-Tax Profit EUR605MAugust 2, 2024 | marketwatch.comMerck Sees Rebound for Semiconductor Business Amid AI BoomAugust 1, 2024 | bloomberg.comMerck cuts annual profit forecastJuly 31, 2024 | msn.comMerck Reports Earnings Tuesday. It Has Big Hopes for Its New Drug Winrevair.July 30, 2024 | msn.comJefferies Reaffirms Their Buy Rating on Merck KGaA (0O14)July 28, 2024 | markets.businessinsider.comGermany's Merck sells pigments unit to China's GNMI for $721 millionJuly 26, 2024 | msn.comMerck to acquire eye drug company EyeBio for up to $3 billionMay 29, 2024 | msn.comMerck to Pay as Much as $3 Billion for Eye Treatment StartupMay 29, 2024 | bloomberg.comGermany's Merck breaks ground on 430 bln-won production line in DaejeonMay 28, 2024 | msn.comMerck KGaA Buys Mirus Bio for $600 MillionMay 23, 2024 | marketwatch.comJustice Department Opts Not to Charge Merck KGaA Subsidiary Over Export Controls SchemeMay 22, 2024 | msn.comMerck stopped a clinical trial for its experimental skin cancer drug after a high rate of side effectsMay 13, 2024 | msn.comMerck Ends Co-Formulation Arm of Keytruda High-Risk Melanoma StudyMay 13, 2024 | marketwatch.comMerck discontinues testing of experimental skin cancer combo therapyMay 13, 2024 | msn.comMerck Keytruda combo meets main goal in late-stage trial for advanced gastric cancerMay 1, 2024 | msn.comMerck KGaA MRKApril 19, 2024 | morningstar.comMerck Highlights Data From Multiple Phase 3 Trials For Its Investigational Pneumococcal Conjugate VaccineMarch 19, 2024 | msn.comFuture Scientists in the Making: MilliporeSigma's Curiosity Cube Wraps Up 2023 Multi-Country STEM TourFebruary 8, 2024 | finanznachrichten.deMerck KGaAJanuary 22, 2024 | wsj.comMerck KGaA ADR MRKCJanuary 3, 2024 | morningstar.comMerck KGaA Q3 Results Down; Now Sees FY23 Earnings In Lower Half Of Estimate RangeNovember 9, 2023 | markets.businessinsider.comHow This New Merck Regimen Could 'Rewrite Textbooks' In Cancer Treatment — And Bolster 4 StocksOctober 22, 2023 | msn.comFDA grants expanded approval for Merck's lung cancer drug KeytrudaOctober 17, 2023 | msn.comEC Approves Merck's KEYTRUDA As Adjuvant Treatment For Non-Small Cell Lung CancerOctober 16, 2023 | markets.businessinsider.comMerck's Lead Cancer Drug Meets Primary Goal In Certain Type Of Lung Cancer PatientsOctober 10, 2023 | msn.comMerck's blood vessel disorder therapy receives US FDA's priority reviewSeptember 28, 2023 | reuters.comMerck and ICR enter renewed cancer drug discovery partnershipSeptember 25, 2023 | msn.comExscientia, Merck KGaA To Discover Drug Candidates Across Oncology, Neuroinflammation & ImmunologySeptember 20, 2023 | markets.businessinsider.comMerck KGaA reports Q2 resultsAugust 3, 2023 | msn.comMerck KGaA Q2 Results Down, Cuts FY23 View; Backs FY25 OutlookAugust 3, 2023 | markets.businessinsider.comGlobal Cell and Gene Therapy Manufacturing Services Market to 2028, Led by Catalent, Lonza, Merck KGaA, and Thermo Fisher ScientificAugust 1, 2023 | finance.yahoo.comMerck Releases Encouraging Data From Two Late-Stage Studies For Pneumococcal Conjugate VaccineJuly 27, 2023 | benzinga.com Get Merck KGaA News Delivered to You Automatically Sign up to receive the latest news and ratings for MKGAY and its competitors with MarketBeat's FREE daily newsletter. Email Address When it comes to NVDA… “acceleration cycles” are the key (Ad)Expert options trader Graham Lindman has been working on a new way to tap into Nvidia’s options… By simply isolating outsized “acceleration cycles” within Nvidia stock (most investors don’t even know it exists)... And thanks to many months and late nights working out the kinks of the systems… They have finally found a way to target these cycles on Nvidia over and over again. Use this link to see Nvidia Unchained right away! MKGAY Media Mentions By Week MKGAY Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. MKGAY News Sentiment▼0.000.49▲Average Medical News Sentiment MKGAY News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. MKGAY Articles This Week▼00▲MKGAY Articles Average Week Get Merck KGaA News Delivered to You Automatically Sign up to receive the latest news and ratings for MKGAY and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies TGIFF News FFNTF News ABSCF News ACONW News ACRDF News ACRHF News ADMT News AGNPF News ALBHF News AKBLF News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (OTCMKTS:MKGAY) was last updated on 11/22/2024 by MarketBeat.com Staff From Our PartnersTrump won. Buy this coin now.Juan Villaverde called the top and bottom of every crypto bull market since 2012. He believes Bitcoin will ...Weiss Ratings | Sponsored[625,000% Gain] – Are You Ready for the Next Altcoin Boom?All of our key indicators are flashing the same signal: an altcoin season is fast approaching. And if you k...Crypto Swap Profits | SponsoredA “Thank You Gift” From Pres. Trump - GeniusThe "Fake Media" has completely ignored Trump's genius "victory gift" to all America First patriots like you. ...Colonial Metals | SponsoredThis company will win the AI race Rome wasn’t built in a day… But there is another lesser-known type of keystone, one that plays an equally c...Porter & Company | Sponsored⭕ [URGENT] Buy Alert just triggeredMy absolute favorite stock just hit a critical "buy now" trigger price.Behind the Markets | SponsoredBuffett's Oil Bet + This 22% Dividend PlayWarren Buffett has been quietly amassing a massive position in oil stocks. But while Buffett's picks (Occid...Investors Alley | Sponsored“Trump Trades” You’ve Got to MakeThese Stocks are the Best “Trump Trades” Free e-book reveals sectors – and stocks within them – likely to p...StockEarnings | SponsoredWhat Comes Next Could Be a Once-in-a-Lifetime OpportunityA wave of technological and financial transformation is reshaping the investment landscape. For those who unde...InvestorPlace | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Merck KGaA Please log in to your account or sign up in order to add this asset to your watchlist. Share Merck KGaA With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
